MARKET

IRD

IRD

Opus Genetics
NASDAQ
4.990
-0.370
-6.90%
After Hours: 5.20 +0.21 +4.21% 19:48 05/08 EDT
OPEN
5.35
PREV CLOSE
5.36
HIGH
5.36
LOW
4.850
VOLUME
1.30M
TURNOVER
--
52 WEEK HIGH
5.81
52 WEEK LOW
0.9011
MARKET CAP
356.30M
P/E (TTM)
-6.2610
1D
5D
1M
3M
1Y
5Y
1D
Analysts Offer Insights on Healthcare Companies: Opus Genetics (IRD), Enovis (ENOV) and Revelation Biosciences (REVB)
TipRanks · 1d ago
Opus Genetics says OPGx-LCA5 trial restores cone-mediated vision in pediatric LCA5 patients
PUBT · 2d ago
Opus Genetics Announces New Clinical And Preclinical Data From Multiple Programs Presented At Association For Research In Vision And Opthalmology Annual Meeting May 3-7
Benzinga · 2d ago
Opus Genetics completes cohort 1 enrollment in Phase 1/2 OPGx-BEST1 gene therapy study
PUBT · 3d ago
OPUS GENETICS INC - THREE-MONTH TOPLINE RESULTS FROM COHORT 1 EXPECTED IN SEPTEMBER 2026
Reuters · 3d ago
FDA Grants RDEP Designation To Opus For OPGx-LCA5 Gene Therapy In Treating LCA5 Retinal Disease
NASDAQ · 5d ago
Opus Genetics Gene Therapy Accepted into FDA's Rare Disease Program
Dow Jones · 5d ago
Opus Genetics announces FDA acceptance of OPGx-LCA5 into RDEP program
TipRanks · 5d ago
More
About IRD
Opus Genetics, Inc. is a clinical-stage ophthalmic biotechnology company. The Company is engaged in developing gene therapies for the treatment of inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. The Company’s pipeline includes adeno-associated virus (AAV)-based investigational gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. Its pipeline also includes OPGx-BEST1 investigational gene therapy, designed to address mutations in the BEST1 gene, which is associated with retinal degeneration. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist being investigated to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 being investigated to slow the progression of non-proliferative diabetic retinopathy.

Webull offers Opus Genetics Inc stock information, including NASDAQ: IRD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IRD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IRD stock methods without spending real money on the virtual paper trading platform.